Compare SMSI & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMSI | AKTX |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.3M | 14.4M |
| IPO Year | 1995 | N/A |
| Metric | SMSI | AKTX |
|---|---|---|
| Price | $0.63 | $0.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.30 |
| AVG Volume (30 Days) | 113.3K | ★ 1.3M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,359,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.57 | $0.26 |
| 52 Week High | $1.95 | $1.73 |
| Indicator | SMSI | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 31.07 |
| Support Level | $0.60 | $0.29 |
| Resistance Level | $0.64 | $0.36 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 85.37 | 25.71 |
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. Its portfolio includes family safety software solutions to support families in the digital age and creating, sharing, and monetizing rich content, such as visual voice messaging, retail content display optimization and performance analytics on any product set. The company's only reportable segment is Wireless. Wireless segment includes the Family Safety (which includes SafePath), CommSuite, and ViewSpot families of products.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.